suvorexant

an orexin receptor antagonist; structure in first source

Also Known As:

(4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; Belsomra; MK 4305; MK-4305; MK4305; methanone, ((7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)-

Networked: 237 relevant articles (51 outcomes, 67 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - suvorexant: 237
  - Azepines: 11
    - suvorexant: 237

Experts

1.	Lines, Christopher: 18 articles (12/2021 - 12/2012)
2.	Herring, W Joseph: 16 articles (12/2021 - 12/2012)
3.	Roth, Thomas: 12 articles (01/2020 - 12/2012)
4.	Michelson, David: 11 articles (12/2021 - 12/2012)
5.	Snyder, Ellen: 11 articles (12/2021 - 12/2012)
6.	Hoyer, Daniel: 8 articles (01/2022 - 01/2013)
7.	Jacobson, Laura H: 8 articles (01/2022 - 01/2013)
8.	Hutzelmann, Jill: 8 articles (12/2021 - 12/2012)
9.	Svetnik, Vladimir: 7 articles (12/2021 - 10/2014)
10.	Krystal, Andrew D: 7 articles (01/2019 - 05/2014)

Related Diseases

1.	Sleep Initiation and Maintenance Disorders (Insomnia) 01/01/2015 - "Our analysis of published trial results suggests that suvorexant is effective in treating primary insomnia and is well-tolerated." 01/01/2019 - "Suvorexant 20/15 mg and 40/30 mg improved sleep to a greater extent than placebo as assessed by the ISI in patients with insomnia. " 01/01/2019 - "Additionally, the "impact of insomnia" component, which assesses the impact of insomnia on daytime function/quality-of-life, was improved to a greater extent by suvorexant than placebo. " 10/01/2014 - "Suvorexant at clinically effective doses had limited effects on power spectral density compared with placebo in healthy subjects and in patients with insomnia, in contrast to the three comparison insomnia treatments. " 01/01/2016 - "Suvorexant: a promising, novel treatment for insomnia."
2.	Delirium 10/06/2020 - "The present study extends to real-world settings previous findings that suvorexant is effective for delirium prevention." 10/01/2018 - "Suvorexant might be effective in preventing delirium in ICU patients." 10/01/2018 - "We investigated whether suvorexant was effective in preventing ICU delirium. " 10/06/2020 - "Previous studies have demonstrated the efficacy of suvorexant for delirium prevention in limited randomized clinical trial settings; however, its effectiveness in everyday clinical settings remains unknown. " 10/01/2020 - "Larger trials comparing the efficacy of suvorexant to other sleep modulating options are necessary to further delineate its role for the prevention of delirium."
3.	Mental Disorders (Mental Disorder) 01/01/2019 - "Suvorexant was beneficial for the treatment of insomnia in people with psychiatric disorders. " 01/01/2021 - "The remaining 41 patients with insomnia who have or not a psychiatric disease who were expected to receive suvorexant treatment were included in this study. " 01/01/2019 - "A larger, long-term study is needed to investigate the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders." 01/01/2019 - "This one-week, prospective, single-arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18-64 or 15 mg if age ≥ 65 years) for insomnia included 57 patients with psychiatric disorders who had experienced any of the following insomnia symptoms for four or more nights during the week prior to the start of the study: total sleep time (TST) <6 hours, time to sleep onset (TSO) ≥30 minutes, or two or more episodes of wake after sleep onset. " 01/01/2019 - "Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study."
4.	Sleep Wake Disorders 02/01/2013 - "In healthy young men without sleep disorders, suvorexant promoted sleep with some evidence of residual effects at the highest doses." 11/01/2020 - "Sleep disorder treatment using suvorexant may provide metabolic benefits for patients with type 2 diabetes." 09/01/2022 - "Sleep disorders can be treated by alleviating difficulties in initiating sleep by changing from suvorexant to lemborexant. " 09/01/2022 - "Effectiveness of change from suvorexant to lemborexant drug in the treatment of sleep disorders." 01/01/2022 - "Although the effects of suvorexant and mirtazapine on sleep and activity are different, both suvorexant and mirtazapine could be potential therapeutic agents for chronic pain-related sleep disorders."
5.	Critical Illness (Critically Ill) 01/01/2022 - "Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study." 05/01/2018 - "Suvorexant was associated with decreased odds of transitioning to delirium in critically ill patients. " 05/01/2018 - "Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study." 05/01/2018 - "Suvorexant is an alternative to benzodiazepines to induce sleep, but the incidence of delirium in critically ill patients is unknown. " 11/07/2022 - "Conclusions: Both suvorexant and lemborexant may be effective in preventing delirium in critically ill adult patients in an advanced critical care center."

Related Drugs and Biologics

1.	Orexin Receptor Antagonists
2.	ramelteon (Rozerem)
3.	lemborexant
4.	Orexin Receptors
5.	Zolpidem (Ambien)
6.	Benzodiazepines
7.	Hypnotics and Sedatives (Sedatives)
8.	Eszopiclone (Lunesta)
9.	Trazodone (Trittico)
10.	almorexant

Related Therapies and Procedures

1.	Self Administration (Administration, Self)
2.	Preoperative Period
3.	Mechanical Ventilators (Ventilator)
4.	Therapeutics
5.	Drug Therapy (Chemotherapy)